Babies born to mothers with opioid use disorder often face a difficult start. They may develop neonatal abstinence syndrome, a condition where they struggle to adjust after leaving the womb. A new analysis looked at how different medications affect these infants. The study included over 5,500 pregnant women taking either buprenorphine or methadone to manage their condition.
The data shows a clear difference in outcomes. Infants exposed to methadone had a higher chance of developing withdrawal symptoms compared to those exposed to buprenorphine-naloxone. These babies also required more medical treatment to manage their symptoms. Furthermore, babies in the buprenorphine group had slightly higher birth weights on average.
This review examined many studies to reach these conclusions. The findings suggest that switching to buprenorphine-based treatments could help newborns avoid severe withdrawal and reduce the need for intensive care. While the study looked at many factors, it is important to remember that every pregnancy is unique. Doctors must weigh these results alongside individual patient needs and medical history.
